Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза II Россия

SYR-472; SYR-472; SYR-472; SYR-472; Placebo

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment With SYR-472 in Subjects With Type 2 Diabetes

Номер протокола01-06-TL-SYR-472-007
ФазаФаза II
Участников по плану — во всех странах исследования369
Сроки01.05.2007 — 01.03.2008
Начало: 1 мая 2007Окончание: 1 марта 2008
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00653185/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: 18–80 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 369 чел. во всех странах исследования.
  • Плановая дата окончания (03.2008) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст18–80 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 17 · невключение: 14

Критерии включения

  • Has a historical diagnosis of type 2 diabetes mellitus.
  • Has undergone less than 7 days of any antidiabetic therapy except lifestyle modification (diet/exercise) within 8 weeks prior to Screening; or has received metformin monotherapy for at least 8 weeks prior to Screening and maintained a stable daily dose of metformin for at least 12 weeks prior to randomization.
  • The subject receiving metformin monotherapy at randomization must have been at least 75% compliant with his or her regimen during the Run-in/Stabilization Period as determined by subject diary and investigator assessment.
  • Has received no treatment with antidiabetic agents other than metformin within the 8 weeks prior to Screening.
  • Has a glycosylated hemoglobin concentration between 7.0% and 10.0%, inclusive, at Screening and at the Week -1 Visit.
  • The subject's fasting C-peptide concentration is greater than or equal to 0.8 ng/mL.
  • Has a fasting plasma glucose concentration less than 275 mg/dL.
  • If regularly uses other non-excluded medications, must be on a stable dose for at least the 4 weeks prior to Screening.
  • Has a systolic blood pressure reading less than 160 mm Hg and a diastolic pressure reading less than 100 mm Hg.
  • Has a hemoglobin value greater than or equal to 12 g/dL for men and greater than or equal to 10 g/dL for women.
  • Has an alanine aminotransferase level is less than or equal to 3 times the upper limit of normal.
  • Males have a serum creatinine value less than 1.5 mg/dL; females have a serum creatinine value less than 1.4 mg/dL.
  • Has a urine albumin/creatinine ratio less than 1000 μg/mg.
  • Has a thyroid-stimulating hormone level less than or equal to the upper limit of the normal range and is clinically euthyroid.
  • Females must be not be pregnant or lactating, and must agree to use adequate contraception throughout the duration of the study.
  • Is able and willing to monitor his or her own blood glucose concentrations with a home glucose monitor.
  • Has no major illness or debility that in the investigator's opinion prohibits the subject from completing the study.

Критерии невключения

  • Is being concurrently treated with antidiabetic therapy other than metformin and lifestyle intervention.
  • Has a history of cancer, other than squamous cell or basal cell carcinoma of the skin that has not been in full remission for at least 5 years prior to Screening.
  • Has a history of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.
  • Has a history of treated diabetic gastric paresis.
  • Has New York Heart Association class III or IV heart failure regardless of therapy.
  • Has a history of coronary angioplasty, underwent coronary stent placement or coronary bypass surgery, or suffered a myocardial infarction, or stroke within the 6 months prior to Screening.
  • Has a history of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.
  • Has a history of infection with human immunodeficiency virus.
  • Has a history of a psychiatric disorder that in the investigator's opinion will affect the subject's ability to participate in the study.
  • Has ingested or received systemically injected glucocorticoids within the 3 months prior to randomization. Inhaled corticosteroids are allowed.
  • Has used prescription or over-the-counter weight-loss drugs within the 3 months prior to randomization.
  • Has received any investigational drug within the 30 days prior to Screening or has received an investigational antidiabetic drug within the 3 months prior to Screening.
  • Has received previous treatment in an investigational study of SYR-472.
  • Has a known hypersensitivity to any compound related to SYR-472.

Источник: ClinicalTrials.gov, NCT00653185 · запись обновлена в реестре 22 июня 2016.

Дизайн и результаты

ДизайнРандомизированное, четверное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)369
Результатыв реестре не опубликованы
Что измеряют — первичные конечные точки (1), вторичных — 14
  • Change from baseline in glycosylated hemoglobin — Weeks 12 or Final Visit.

Цель исследования

The purpose of this study is to determine the efficacy, safety and tolerability of SYR-472, once daily (QD), in subjects with Type 2 Diabetes Mellitus.

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00653185 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.